
EquitySector - HealthcareVery High Risk
Regular
NAV (27-Aug-26)
Returns (Since Inception)
Fund Size
₹5,400 Cr
Expense Ratio
2.00%
ISIN
INF200K01446
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
31 Dec 2004
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+21.07%
+17.81% (Cat Avg.)
3 Years
+23.86%
+21.74% (Cat Avg.)
5 Years
+18.07%
+15.00% (Cat Avg.)
10 Years
+13.95%
+14.83% (Cat Avg.)
Since Inception
+15.74%
— (Cat Avg.)
| Equity | ₹5,307.69 Cr | 98.29% |
| Debt | ₹2.95 Cr | 0.05% |
| Others | ₹89.24 Cr | 1.65% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹686.72 Cr | 12.72% |
| Divi's Laboratories Ltd | Equity | ₹402.8 Cr | 7.46% |
| Acutaas Chemicals Ltd | Equity | ₹279.44 Cr | 5.17% |
| Cipla Ltd | Equity | ₹274.02 Cr | 5.07% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹268.71 Cr | 4.98% |
| Torrent Pharmaceuticals Ltd | Equity | ₹256.14 Cr | 4.74% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹247.16 Cr | 4.58% |
| Laurus Labs Ltd | Equity | ₹217.94 Cr | 4.04% |
| Aurobindo Pharma Ltd | Equity | ₹208.59 Cr | 3.86% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹197.32 Cr | 3.65% |
| Biocon Ltd | Equity | ₹159.64 Cr | 2.96% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹155.44 Cr | 2.88% |
| Anthem Biosciences Ltd | Equity | ₹152.13 Cr | 2.82% |
| Gland Pharma Ltd | Equity | ₹150.17 Cr | 2.78% |
| Fortis Healthcare Ltd | Equity | ₹141.75 Cr | 2.63% |
| Treps | Cash - Repurchase Agreement | ₹138.3 Cr | 2.56% |
| Sai Life Sciences Ltd | Equity | ₹131.51 Cr | 2.44% |
| Aether Industries Ltd | Equity | ₹123.17 Cr | 2.28% |
| Sudeep Pharma Ltd | Equity | ₹119.82 Cr | 2.22% |
| Poly Medicure Ltd | Equity | ₹108.93 Cr | 2.02% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹107.12 Cr | 1.98% |
| Ajanta Pharma Ltd | Equity | ₹103.96 Cr | 1.93% |
| Concord Biotech Ltd | Equity | ₹102.3 Cr | 1.89% |
| Mankind Pharma Ltd | Equity | ₹98.78 Cr | 1.83% |
| Lupin Ltd | Equity | ₹96.6 Cr | 1.79% |
| Cohance Lifesciences Ltd | Equity | ₹93.51 Cr | 1.73% |
| Global Health Ltd | Equity | ₹89.96 Cr | 1.67% |
| Nephrocare Health Services Ltd | Equity | ₹64.95 Cr | 1.20% |
| Dr. Lal PathLabs Ltd | Equity | ₹57.16 Cr | 1.06% |
| Abbott India Ltd | Equity | ₹55.6 Cr | 1.03% |
| Syngene International Ltd | Equity | ₹51.58 Cr | 0.96% |
| Net Receivable / Payable | Cash - Collateral | ₹-49.06 Cr | 0.91% |
| Rainbow Childrens Medicare Ltd | Equity | ₹45.76 Cr | 0.85% |
| HealthCare Global Enterprises Ltd | Equity | ₹39.53 Cr | 0.73% |
| Gufic Biosciences Ltd | Equity | ₹19.49 Cr | 0.36% |
| Day Tbill | Bond - Gov't/Treasury | ₹2.95 Cr | 0.05% |
Large Cap Stocks
34.97%
Mid Cap Stocks
31.10%
Small Cap Stocks
32.22%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹4,905.08 Cr | 90.84% |
| Basic Materials | ₹402.61 Cr | 7.46% |
Standard Deviation
This fund
14.36%
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
1.10
Cat. avg.
0.90
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.55
Higher the better
Since June 2011
ISIN INF200K01446 | Expense Ratio 2.00% | Exit Load No Charges | Fund Size ₹5,400 Cr | Age 21 years 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹12,88,262 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments